Evidence map›Paper›PMID 37199529›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.

Akash Virupakshaiah, Dimitrios C Ladakis, Bardia Nourbakhsh, Pavan Bhargava, Sonam Dilwali, Vinicius Schoeps, Kamil Borkowski, John W Newman, Emmanuelle Waubant

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Metabolic and lipid alterations in multiple sclerosis linked to disease severity.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Akash VirupakshaiahDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2624-9974
Dimitrios C LadakisDivision of Neuroimmunology, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-5764-2114
Bardia NourbakhshDivision of Neuroimmunology, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-6617-2003
Pavan BhargavaDivision of Neuroimmunology, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-7947-9418
Sonam DilwaliDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Vinicius SchoepsDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8875-0567
Kamil BorkowskiWest Coast Metabolomics Center, University of California Davis, Davis, CA, USA.
John W NewmanWest Coast Metabolomics Center, University of California Davis, Davis, CA, USA United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, Davis, CA, USA Department of Nutrition, University of California Davis, Davis, CA, USA.
Emmanuelle WaubantDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USJohns Hopkins University · USUnited States Department of Agriculture · USUniversity of California, Davis · US

Funding

Environmental and genetic risk factors for pediatric MSR01NS071463 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WAUBANT, EMMANUELLE LAURENCE · 2010 to 2015
$2.8M
NINDS NIH HHS R01 NS071463
6 · The paper itself

Abstract

backgroundThe circulating metabolome is altered in multiple sclerosis (MS), but its prognostic capabilities have not been extensively explored. Lipid metabolites might be of particular interest due to their multiple roles in the brain, as they can serve as structural components, energy sources, and bioactive molecules. Gaining a deeper understanding of the disease may be possible by examining the lipid metabolism in the periphery, which serves as the primary source of lipids for the brain.

objectiveTo determine if altered serum lipid metabolites are associated with the risk of relapse and disability in children with MS.

methodsWe collected serum samples from 61 participants with pediatric-onset MS within 4 years of disease onset. Prospective longitudinal relapse data and cross-sectional disability measures (Expanded Disability Status Scale [EDSS]) were collected. Serum metabolomics was performed using untargeted liquid chromatography and mass spectrometry. Individual lipid metabolites were clustered into pre-defined pathways. The associations between clusters of metabolites and relapse rate and EDSS score were estimated utilizing negative binomial and linear regression models, respectively.

resultsWe found that serum acylcarnitines (relapse rate: normalized enrichment score [NES] = 2.1,

conclusionThis study supports the role of some lipid metabolites in pediatric MS relapses and disability.

Indexed as

Multiple SclerosisChildChronic DiseaseCross-Sectional StudiesDisability EvaluationDisease ProgressionFatty Acids, UnsaturatedHumansProspective StudiesRecurrenceFatty Acids, UnsaturatedEDSSlipidomicsPediatric onset MSrelapse rate

Identifiers

PMID37199529
PMCPMC10524330
OpenAlexW4377011379

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.